Magdaliz Gorritz
YOU?
Author Swipe
View article: Geographic Distribution of Gastroenterologists and Patients With Inflammatory Bowel Disease in the United States
Geographic Distribution of Gastroenterologists and Patients With Inflammatory Bowel Disease in the United States Open
Introduction: We aimed to map the distribution of patients with inflammatory bowel disease (IBD) and gastroenterologists throughout the US and identify local and state-level variations in the availability of specialist care. Methods: For e…
View article: Real-world persistence and adherence of ofatumumab versus oral and injectable disease-modifying therapies in patients with multiple sclerosis
Real-world persistence and adherence of ofatumumab versus oral and injectable disease-modifying therapies in patients with multiple sclerosis Open
OMB showed better persistence and adherence compared with platform self-injectable DMTs, as well as better persistence compared with oral DMTs. This real-world analysis provides additional insights into OMB utilization among patients with …
View article: REAL-WORLD RATE AND MAGNITUDE OF DOSE ESCALATION WITH BIOLOGICS IN PATIENTS WITH CROHN’S DISEASE
REAL-WORLD RATE AND MAGNITUDE OF DOSE ESCALATION WITH BIOLOGICS IN PATIENTS WITH CROHN’S DISEASE Open
INTRODUCTION Advanced therapies (ATs), such as adalimumab (ADA), infliximab (INF), vedolizumab (VED), and ustekinumab (UST), referred to as biologics, are regularly used to treat moderate-to-severe Crohn’s disease (CD). Loss of response is…
View article: REAL-WORLD RATE AND MAGNITUDE OF DOSE ESCALATION WITH BIOLOGICS IN PATIENTS WITH ULCERATIVE COLITIS
REAL-WORLD RATE AND MAGNITUDE OF DOSE ESCALATION WITH BIOLOGICS IN PATIENTS WITH ULCERATIVE COLITIS Open
INTRODUCTION Advanced therapies (ATs), such as adalimumab (ADA), infliximab (INF), golimumab (GOL), vedolizumab (VED), and ustekinumab (UST), referred to as biologics, are regularly used to treat moderate-to-severe ulcerative colitis (UC).…
View article: Real-World Efficacy and Tolerability of Brigatinib in Patients with Non-Small Cell Lung Cancer with Prior ALK-TKIs in the United States
Real-World Efficacy and Tolerability of Brigatinib in Patients with Non-Small Cell Lung Cancer with Prior ALK-TKIs in the United States Open
Background Real-world evidence for brigatinib, a next-generation anaplastic lymphoma kinase-tyrosine kinase inhibitor (ALK-TKI) used in ALK-rearranged non-small cell lung cancer, is scarce. This retrospective study evaluated real-world bri…
View article: Previously unrecognized risk factors for severe hypoglycaemia requiring emergency medical care in insulin‐treated type 2 diabetes: Results from a real‐world nested case‐control study
Previously unrecognized risk factors for severe hypoglycaemia requiring emergency medical care in insulin‐treated type 2 diabetes: Results from a real‐world nested case‐control study Open
Aim Several risk factors for severe hypoglycaemia (SH) are associated with insulin‐treated diabetes. This study explored potential risk factors in adults with insulin‐treated type 2 diabetes mellitus (T2DM). Materials and Methods In this c…
View article: US health care utilization and costs in adult patients with atopic dermatitis by disease severity
US health care utilization and costs in adult patients with atopic dermatitis by disease severity Open
BACKGROUND: Although previous studies have reported the economic burden of atopic dermatitis (AD) in adults, updates are needed using more current data and measure of disease severity. OBJECTIVE: To describe the health care resource utiliz…
View article: The Incidence, Prevalence, and Associated Costs of Anemia, Malignancy, Venous Thromboembolism, Major Adverse Cardiovascular Events, and Infections in Rheumatoid Arthritis Patients by Treatment History in the United States
The Incidence, Prevalence, and Associated Costs of Anemia, Malignancy, Venous Thromboembolism, Major Adverse Cardiovascular Events, and Infections in Rheumatoid Arthritis Patients by Treatment History in the United States Open
Objective Comorbidities in rheumatoid arthritis (RA) can influence treatment selection, impact treatment persistency, and increase health care costs. This study assessed the magnitude of comorbidity burden via epidemiology (incidence and p…
View article: Inadequate response and treatment patterns in adults diagnosed with atopic dermatitis and treated with topical therapy
Inadequate response and treatment patterns in adults diagnosed with atopic dermatitis and treated with topical therapy Open
Treatment for atopic dermatitis (AD) is complex, particularly in patients with inadequate response to topical therapies. Currently, there is little clinical guidance for the treatment of these patients. A real-world retrospective study uti…
View article: The current treatment landscape in adult atopic dermatitis in the United States: results from a cross-sectional real-world study
The current treatment landscape in adult atopic dermatitis in the United States: results from a cross-sectional real-world study Open
This study describes the current treatment landscape in adult atopic dermatitis (AD), overall and by disease severity. Adult patients with an AD diagnosis in dermatology-specific electronic medical records during 2018 were identified and l…
View article: Identifying disability level in multiple sclerosis patients in a U.S.-based health plan claims database
Identifying disability level in multiple sclerosis patients in a U.S.-based health plan claims database Open
The CDS is the first claims-based measure of MS disability utilizing data from EMR. This novel measure advances the opportunity to examine outcomes by disability accumulation in the absence of standard markers of disease progression. Altho…
View article: Inpatient and outpatient treatment patterns of cancer-associated thrombosis in the United States
Inpatient and outpatient treatment patterns of cancer-associated thrombosis in the United States Open
Low molecular weight heparins (LMWHs) and direct oral anticoagulants (DOACs) are among the recommended treatment options for cancer-associated thrombosis (CAT) in the 2019 National Comprehensive Care Network guidelines. Little is known abo…